NCT00492570已完成不适用
GER-009-06-AVX Early Therapy in Multiple Sclerosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 230
研究概览
简要总结
This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.
详细描述
This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CIS (according to indication) or early Relapsing Remitting Multiple Sclerosis
排除标准
- •treatment with DMT during the last 12 months
研究者
相似试验
已完成
4 期
Long Term Study of Avonex Therapy Following a First Attack of Multiple SclerosisTransverse MyelitisAcute Brainstem/Cerebellar SyndromeMultiple SclerosisOptic NeuritisNCT00179478Beth Israel Deaconess Medical Center155
已完成
2 期
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.Relapsing Remitting Multiple SclerosisNCT00203073Teva Branded Pharmaceutical Products R&D, Inc.40
已完成
不适用
Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study TwoNL-OMON27332Genzyme Corporation700
Unknown
不适用
Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimERelapsing Remitting Multiple SclerosisNCT05446285NHS Greater Glasgow and Clyde245
已完成
不适用
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple SclerosisRelapsing Remitting Multiple SclerosisNCT00203086Teva Branded Pharmaceutical Products R&D, Inc.30